Cardiovascular Disease: to HAART or not to HAART MOAB2
Please enter your email :
Type:
Oral Abstract Session Back
Venue: Session Room 1
Time: 16:30 - 18:00, 20.07.2009
Code: MOAB2
Chairs: Dominique Costagliola, France
Judith Currier, United States
Session recording provided by International AIDS Society



Presentations in this session:

16:30
MOAB201
Powerpoint		The current debate on abacavir; risks and relationship between HIV viremia and cardiovascular events
Presented by Dominique Costagliola, France



16:40
MOAB202
Abstract
Powerpoint		Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era
Presented by Roger Bedimo, United States
R. Bedimo1,2, A. Westfall3, H. Drechsler1,2, P. Tebas4
1VA North Texas Healthcare System, Medicine, Dallas, United States, 2University of Texas Southwestern Medical Center, Medicine, Dallas, United States, 3University of Alabama at Birmingham, Medicine, Birmingham, United States, 4University of Pennsylvania, Medicine, Philadelphia, United States

16:55
MOAB203
Abstract
Powerpoint		No evidence for recent abacavir/lamivudine use in promoting inflammation, endothelial dysfunction,hypercoagulability, or insulin resistance in virologically suppressed HIV-infected patients: a substudy of the BICOMBO randomized clinical trial (ISRCTN61891868)
Presented by Esteban Martinez, Spain
E. Martinez1, M. Larrousse1, I. Perez1, M. Loncá1, D. Podzamczer2, F. Gutierrez3, R. Deulofeu1, R. Casamitjana1, J.C. Reverter1, J. Mallolas1, J. Pich1, J.M. Gatell1, for the BICOMBO Study Group
1Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain, 2Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain, 3Hospital General Universitario de Elche, Elche, Spain

17:10
MOAB204
Abstract		Duration of HIV infection is associated with carotid artery stiffness
Presented by Eric C. Seaberg, United States
E.C. Seaberg1, A.R. Sharrett1, H.N. Hodis2, W.J. Mack2, L.A. Kingsley3, L. Benning1, R.C. Kaplan4, J.P. Phair5, Multicenter AIDS Cohort Study (MACS)
1Johns Hopkins University Bloomberg School of Public Health, Department of Epidemiology, Baltimore, United States, 2Keck School of Medicine, University of Southern California, Los Angeles, United States, 3University of Pittsburgh, Pittsburgh, United States, 4Albert Einstein College of Medicine, New York, United States, 5Northwestern University, Chicago, United States

17:25
MOAB205
Abstract
Powerpoint		Coronary vasomotor function is reduced after initiation of antiretroviral therapy in treatment naïve HIV patients: a prospective myocardial perfusion PET study
Presented by Ulrik Sloth Kristoffersen, Denmark
U.S. Kristoffersen1,2, A.-M. Lebech3, J. Gerstoft4, N. Wiinberg5, H. Gutte1,2, C.L. Petersen5, A. Kjaer1,2
1Copenhagen University Hospital, Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen, Denmark, 2University of Copenhagen, Cluster for Molecular Imaging, Copenhagen, Denmark, 3Hvidovre University Hospital, Department of Infectious Diseases, Copenhagen, Denmark, 4Copenhagen University Hospital, Rigshospitalet, Department of Infectious Diseases, Copenhagen, Denmark, 5Frederiksberg Hospital, Department of Clinical Physiology and Nuclear Medicine, Copenhagen, Denmark

17:40
MOAB206
Abstract
Powerpoint		A 14-day treatment with a cyclooxygenase 2 (COX-2) inhibitor reduces inflammation in the lymphoid tissues of HIV-infected patients without HAART - a pilot study with positron emission tomography (PET/CT) assessment
Presented by Jean-Christophe Goffard, Belgium
N. Witvrouw1, G. Darcis2, G. Gaudray3, N. Schaaf-Lafontaine4, R. Hustinx5, K. Schepers6, M. Moutschen2, C. Meuris2
1CHU Liege, Nuclear Medicine, Liege, Belgium, 2University of Liege/CHU Liege, AIDS Reference Center, Liege, Belgium, 3University of Liege, GIGA Research, Liege, Belgium, 4University of Liege/CHU Liege, Laboratory of Hematology, Liege, Belgium, 5University of Liege/CHU Liege, Nuclear Medicine, Liege, Belgium, 6Université Libre de Bruxelles (ULB)/Erasme Hospital, AIDS Reference Center, Brussels, Belgium

Powerpoints presentations
The current debate on abacavir; risks and relationship between HIV viremia and cardiovascular events - Costagliola

Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era - Bedimo

No evidence for recent abacavir/lamivudine use in promoting inflammation, endothelial dysfunction,hypercoagulability, or insulin resistance in virologically suppressed HIV-infected patients: a substudy of the BICOMBO randomized clinical trial (ISRCTN61891868) - Martinez


Coronary vasomotor function is reduced after initiation of antiretroviral therapy in treatment naïve HIV patients: a prospective myocardial perfusion PET study - Kristoffersen

A 14-day treatment with a cyclooxygenase 2 (COX-2) inhibitor reduces inflammation in the lymphoid tissues of HIV-infected patients without HAART - a pilot study with positron emission tomography (PET/CT) assessment - Goffard



Rapporteur report

Track B report by Ian Frank, Pablo Tebas, Renslow Sherer and Roger Bedimo


Not surprisingly the session started with presentations related to the presumed role of abacavir in increasing the risk of cardiovascular events in patients with HIV infection, a topic that has been in the mind of clinicians, patients, and researchers since the original presentation of this data by the DAD group in 2007.

Bedimo et al. presented a large epidemiological study of the VA cohort that included more than 19000 participants. In this cohort the use of abacavir was marginally associated with an increased cardiovascular risk, and the association disappeared after adjusting for traditional risk factors, renal function (the main reason ABC is used instead of tenofovir) and HCV. Importantly, renal dysfunction was an additional strong predictor of cardiovascular risk.

Esteban Martinez et al. asked the question: if abacavir is associated with an increased cardiovascular risk, then what is the biological mechanism? The Spanish group looked at 80 patients of the BICOMBO study in which fully supressed individuals were randomized to receive abacavir/3TC or TFV/3TC. The authors did not see any difference between the two groups in markers of inflammation, endothelial function, coagulation, cytokines and insulin resistence, which  increased cardiovascular risk in other studies.  

Seaberg of the MACS cohort compared the carotid stiffness, a surrogate of the subsequent risk of atherosclerosis, of individuals with known duration of HIV infection with seronegative controls. The longer the duration of HIV infection, after controling for traditional risk factors, the higher the carotid stifness, suggesting that HIV itself, increases the cardiovascular risk of HIV infected patients.

In the small study of Kristofersen (N=11) the initiation of ART was associated with decrease in the vasomotor function, linking the use of ART with a proatherogenic effect in the heart. This study and the BICOMBO study are limited by the small numbers of patients in each cohort

Finally, in the study of Witvrouw et al. the use of a 14 days of a COX-2 inhibitor in antiretroviral naive individuals decreased the inflammation of the lymph nodes.


   

   

    The organizers reserve the right to amend the programme.
Contact Us | Site map © 2009 International AIDS Society